Therapy scheme for rheumatoid arthritis. The triple combination of methotrexate plus sulfasalazine plus hydroxychloroquine is more than just an alternative to leflunomidex;Therapy scheme for rheumatoid arthritis. The triple combination of methotrexate plus sulfasalazine plus hydroxychloroquine is more than just an alternative to leflunomide

Aktuelle Rheumatologie

Volumn 35, Issue 2, 2010, Pages 129-131

  Zeidler, H ^a  

^a Medizin Rheumatologikum Hannover ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

DRUG EFFICACY; HUMAN; LETTER; LIVER TOXICITY; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 77951881705     PISSN: 0341051X     EISSN: 14389940     Source Type: Journal    
DOI: 10.1055/s-0030-1248294     Document Type: Letter

References (30)

1. Agarwal S, Zaman T, Handa R. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 2009 50 686-692
2. Aletaha D, Stamm T, Kapral T, etal. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003 62 944-951
3. Antony T, Jose VM, Paul BJ, etal. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci 2006 60 318-326
4. Curtis JR, Beukelman T, Onofrei A, etal. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69 4347
5. Glaeske G, Schicktanz C, Janhsen K. GEK-Arzneimittel-Report 2009. Schriftenreihe zur Gesundheitsanalyse, Band 68. St. Augustin: Asgard 2009
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, etal. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005 52 3381-3390
7. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, etal. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007 146 406-415
8. Grigor C, Capell H, Stirling A, etal. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004 364 263-269
9. Gromnica-Ihle E. Pharmakotherapie der rheumatoiden. Arthritis. Z Rheumatol 2002 61 (Suppl 2) II/35-II/38
10. Korpela M, Laasonen L, Hannonen P, etal. for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study group. Arthritis Rheum 2004 50 2072-2081
11. Kremer J, Genovese M, Cannon GW, etal. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomi-zed, double-blind, placebo controlled trial. J Rheumatol 2004 31 1521-1531
12. Kremer JM, Genovese MC, Cannon GW, etal. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004 31 1521-1531
13. Lee SS, Park YW, Park JJ, etal. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol 2009 38 11-14
14. Leirisalo-Repo M, Kautiainen H, Laasonen L, Mttnen T, etal. A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACO DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACO study. Ann Rheum Dis 2008 67 (Suppl II) 50
15. Mttnen T, Hannonen P, Leirisalo-Repo M, etal. for the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999 353 1568-1573
16. ODell JR, Haire CE, Erikson N, etal. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996 334 1287-1291
17. ODell JR, Leff R, Paulsen G, etal. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002 46 1164-1170
18. Proudman SM, Keen HI, Stamp LK, etal. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007 37 99-111
19. Puolakka K, Kautiainen H, Mottonen T, etal. for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five year experience from the FIN-RACo trial. Arthritis Rheum 2005 52 36-41
20. Rantalaiho V, Korpela M, Hannonen P, etal. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009 60 1222-1231
21. Saunders SA, Capell HA, Stirling A, etal. Triple therapy in early active rheumatoid arthritis. A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008 58 1310-1317
22. Schoels M, Kapral T, Stamm T, etal. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis 2007 66 1059-1065
23. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009 374 459-466
24. Van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, etal. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009 61 291-299
25. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, etal. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007 66 1356-1362
26. Vollenhoven van R F, Ernestam S, Geborek P, etal. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009 374 459-466
27. Weinblatt ME, Kremer JM, Coblyn JS, etal. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999 42 1322-1328
28. Wollenhaupt J, Alten R, Backhaus M, etal. Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. Akt Rheumatol 2009 34 234-239
29. Wollenhaupt J, Alten R, Burkhardt H, etal. Aktuelle Therapiestrategien bei rheumatoider Arthritis. Entzndung rasch beherrschen ist entscheidend fr die Prognose. MMW 2006 148 (Heft 42) 38-42
30. Zeidler H, Wollenhaupt J. Kombination von Basistherapeutika. Von der individuellen Hoffnung zum gezielten Einsatz. Z Rheumatol 2001 60 477-480